<code id='DEDD83A6B0'></code><style id='DEDD83A6B0'></style>
    • <acronym id='DEDD83A6B0'></acronym>
      <center id='DEDD83A6B0'><center id='DEDD83A6B0'><tfoot id='DEDD83A6B0'></tfoot></center><abbr id='DEDD83A6B0'><dir id='DEDD83A6B0'><tfoot id='DEDD83A6B0'></tfoot><noframes id='DEDD83A6B0'>

    • <optgroup id='DEDD83A6B0'><strike id='DEDD83A6B0'><sup id='DEDD83A6B0'></sup></strike><code id='DEDD83A6B0'></code></optgroup>
        1. <b id='DEDD83A6B0'><label id='DEDD83A6B0'><select id='DEDD83A6B0'><dt id='DEDD83A6B0'><span id='DEDD83A6B0'></span></dt></select></label></b><u id='DEDD83A6B0'></u>
          <i id='DEDD83A6B0'><strike id='DEDD83A6B0'><tt id='DEDD83A6B0'><pre id='DEDD83A6B0'></pre></tt></strike></i>

          focus

          focus

          author:entertainment    Page View:8967
          In this photo illustration, Farxiga, Xarelto, Entresto, and Eliquis are made available to customers at the New City Halsted Pharmacy on August 29, 2023 in Chicago, Illinois. These are 4 of 10 prescription drugs that will be subject to Medicare price negotiations under the Inflation Reduction Act. The other drugs include Jardiance, Enbrel, Januvia, Imbruvica, Stelara and Fiasp.
          Scott Olson/Getty Images

          WASHINGTON  — The Biden administration is making its opening offers to pharmaceutical companies in its brand-new Medicare drug price negotiation program on Thursday, administration officials said. And that’s about all they said.

          The offers will not be made public unless a manufacturer chooses to publicly disclose information about the talks, a senior administration official said. Companies have until March 2 to either accept the government’s offer or propose a counteroffer. The Biden administration will publish the final prices by Sept. 1 of this year after the negotiation process ends. 

          advertisement

          The negotiated prices won’t take effect until 2026. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Bright Health sells Medicare Advantage business to Molina
          Bright Health sells Medicare Advantage business to Molina

          BrightHealthisofficiallyleavingthehealthinsurancemarket.ThecompanyhasagreedtosellitsMedicareAdvantag

          read more
          EHR maker NextGen Healthcare to pay $31M to resolve fraud claims
          EHR maker NextGen Healthcare to pay $31M to resolve fraud claims

          AdobeThehealthrecordscompanyNextGenHealthcarewillpay$31milliontoresolveallegationsthatitpaidkickback

          read more
          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more

          Sanofi seeks simpler, safer CRISPR sickle cell cure

          RubyWallauforSTATSanofiwilllicenseanewCRISPRenzymefromthestartupScribeTherapeuticsinabidtobethefirst